Menu Search
Equities

Procaps Group SA

PROC:NMQ

Procaps Group SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.87
  • Today's Change0.06 / 3.31%
  • Shares traded516.00
  • 1 Year change-49.46%
  • Beta0.1553
Data delayed at least 15 minutes, as of Sep 19 2024 16:42 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Procaps Group SA share price to rise to 5.00 in the next year from the last price of 1.81.
High176.2%5.00
Med176.2%5.00
Low176.2%5.00

Earnings history & estimates in USD

On Dec 26, 2023, Procaps Group SA reported 3rd quarter 2023 earnings of 0.08 per share. This result was in line with the expectation of the one analyst following the company and under-performed last year's 3rd quarter results by 63.64%.
Average growth rate+32.70%
Procaps Group SA reported annual 2022 earnings of 0.42 per share on May 12, 2023.
More ▼

Revenue history & estimates in USD

Union Acquisition Corp. II had 3rd quarter 2023 revenues of 118.41m. This bettered the 110.40m estimate of the one analyst covering the company. This was 38.33% above the prior year's 3rd quarter results.
Average growth rate+3.30%
Union Acquisition Corp. II had revenues for the full year 2022 of 409.92m. This was 0.04% above the prior year's results.
Average growth rate+0.04%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.